Biotech sector setup for catch-up rally
Carter Worth and the panel argued that biotech is completing a long-term bottoming process and offers relative and absolute upside as M&A accelerates.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.